Sitravatinib malate + Nivolumab is a small molecule commercialized by Mirati Therapeutics, with a leading Phase III program in Solid Tumor. According to Globaldata, it is involved in 35 clinical trials, of which 10 were completed, 23 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Sitravatinib malate + Nivolumab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Sitravatinib malate + Nivolumab is expected to reach an annual total of $572 mn by 2032 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sitravatinib malate + Nivolumab Overview
Sitravatinib malate is under development for the treatment of renal cell carcinoma, gallbladder cancer, advanced biliary tract cancer, oral cavity cancer, metastatic urothelial tract cancer (bladder cancer), gastroesophageal junction carcinoma, metastatic triple negative breast cancer, non-small cell lung cancer, metastatic hepatocellular carcinoma, renal cell carcinoma, epithelial ovarian carcinoma, liposarcoma, well-differentiated or de-differentiated liposarcoma, soft tissue sarcomas, peripheral nerve sheath Tumor (neurofibrosarcoma), synovial sarcoma, rhabdomyosarcoma, endometrial cancer, esophageal squamous cell carcinoma, metastatic uveal melanoma and metastatic melanoma. The drug candidate is administered orally. It is a second generation multi-targeted kinase inhibitor. It inhibits RET, TRK, DDR and EphRs as well as Met, Axl and VEGFRs (VEGFR 1, 2 3), c-Met, PDGFR and KIT. It was under development for squamous cell carcinoma of head and neck, metastatic castrate-resistant prostate cancer with bone metastasis, thymoma and squamous non-small cell lung cancer.
Mirati Therapeutics Overview
Mirati Therapeutics is a clinical-stage oncology company that developing novel therapeutics to address the genetic and immunological promoters of cancer. The company product pipeline includes Adagrasib (MRTX849), an oral small molecule inhibitor of KRASG12C and MRTX1133, a potent small molecule inhibitor of the KRASG12D for the treatment of colorectal and pancreatic cancer. Mirati Therapeutics is also evaluating Sitravatinib, a multi kinase inhibitor against non-small cells lung cancer in non-smokers and MRTX1719 to treat MTAP deleted cancers. The company has partner with Zai Lab, Beigene, Sanofi, Boehringer, Novartis and Bristol Myers Squibb, among others. It operates in Canada, Netherlands and the US. Mirati Therapeutics is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$72.1 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$13.4 million in FY2020. The operating loss of the company was US$573.2 million in FY2021, compared to an operating loss of US$369.4 million in FY2020. The net loss of the company was US$581.8 million in FY2021, compared to a net loss of US$357.9 million in FY2020. The company reported revenues of US$5.4 million for the third quarter ended September 2022, an increase of 1.3% over the previous quarter.
For a complete picture of Sitravatinib malate + Nivolumab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.